Robert L Jerzewski

8598185, Dec 3, 2013

Jun 13, 2006

11/453122

Terrence C. Dahl - Sunnyvale CA, US
Munir A. Hussain - Belle Mead NJ, US
Robert A. Lipper - Pennington NJ, US
Robert L. Jerzewski - Belle Mead NJ, US
Mark M. Menning - San Francisco CA, US
Reza Oliyai - San Carlos CA, US
Taiyin Yang - Saratoga CA, US

Bristol-Myers Squibb & Gilead Sciences, Inc. - Foster City CA

A61K 31/551
A61K 31/522
A61K 31/513

51426332, 514269, 514221

In accordance with this invention a novel pharmaceutical product containing efavirenz, emtricitabine and tenofovir DF are provided as a multicomponent unitary oral dosage form, component 1 comprising tenofovir DF (and, optionally, emtricitabine) and component 2 comprising efavirenz, wherein components 1 and 2 are in a stabilizing configuration. In preferred embodiments component 1 is made by dry granulation.

20040005358, Jan 8, 2004

Apr 21, 2003

10/419397

Peter Slugg - Princeton NJ, US
Nemichand Jain - West Windsor NJ, US
Rajesh Krishna - West Windsor NJ, US
Robert Jerzewski - Belle Mead NJ, US
Ronald Smith - Yardley PA, US
Jatin Patel - West Windsor NJ, US
Bimal Malhotra - New Brunswick NJ, US

A61K031/554
A61K009/22

424/468000, 514/211050

A modified-release vasopeptidase inhibitor formulation is provided which is capable of releasing vasopeptidase inhibitor, preferably omapatrilat or gemopatrilat, in a manner to provide therapeutically effective NEP inhibitory activity and therapeutically effective ACE inhibitory activity, in a balanced manner, for a predetermined duration to lower blood pressure and/or treat heart failure. In a preferred formulation, the NEP inhibitory activity and ACE inhibitory activity have balanced release characteristics. Combinations including the above formulation and a diuretic and/or other therapeutic agents and methods for lowering blood pressure employing the above formulation and/or combination and a method for enhancing or balancing NEP inhibitory activity of a vasopeptidase inhibitor are also provided.

50063448, Apr 9, 1991

Jun 26, 1990

7/543639

Robert L. Jerzewski - East Millstone NJ
Thomas M. Wong - North Brunswick NJ
Lewis J. Gryziewicz - North Brunswick NJ
Nemichand B. Jain - Monmouth Junction NJ
Ajit B. Thakur - East Brunswick NJ

E. R. Squibb & Sons, Inc. - Princeton NJ

A61K 920

424465

Shelf stable tablets containing fosinopril sodium are prepared by employing either sodium stearyl fumarate or hydrogenated vegetable oil as the lubricant. The tablets can contain conventional excipients such as fillers, binders, and disintegrants as well as an optional diuretic.

55062482, Apr 9, 1996

May 22, 1995

8/445623

Faranak Nikfar - Bridgewater NJ
Abu T. M. Serajuddin - Flushing NY
Robert L. Jerzewski - Belle Mead NJ
Nemichand B. Jain - Cranbury NJ

Bristol-Myers Squibb Company - Princeton NJ

A61K 3142

514374

An ifetroban composition is provided which has good dissolution properties even on aging, when dispersed in water has a pH of at least 7 and includes a salt of ifetroban, one or more basifying agents, such as magnesium oxide or calcium carbonate, and where in tablet form includes one or more fillers such as mannitol and/or microcrystalline cellulose, one or more disintegrating agents such as crospovidone, one or more lubricants such as magnesium stearate, optionally one or more glidants such as colloidal silicon dioxide, one or more binders such as pregelatinized starch (dry binder) or polyvinyl-pyrrolidone (wet binder) and optionally a film coating containing a film former such as hydroxypropyl cellulose and a plasticizer such as 1,2,3-propanetriol triacetate.

20170079999, Mar 23, 2017

Dec 6, 2016

15/370588

- Foster City CA, US
Munir A. HUSSAIN - Belle Mead NJ, US
Robert A. LIPPER - Pennington NJ, US
Robert L. JERZEWSKI - Belle Mead NJ, US
Mark M. MENNING - San Francisco CA, US
Reza OLIYAI - Burlingame CA, US
Taiyin YANG - Monte Sereno CA, US

A61K 31/683

In accordance with this invention a novel pharmaceutical product containing efavirenz, emtricitabine and tenofovir DF are provided as a multicomponent unitary oral dosage form, component 1 comprising tenofovir DF (and, optionally, emtricitabine) and component 2 comprising efavirenz, wherein components 1 and 2 are in a stabilizing configuration. In preferred embodiments component 1 is made by dry granulation.

20150174147, Jun 25, 2015

Mar 6, 2015

14/640825

- Foster City CA, US
Munir A. HUSSAIN - Belle Mead NJ, US
Robert A. LIPPER - Pennington NJ, US
Robert L. JERZEWSKI - Belle Mead NJ, US
Mark M. MENNING - San Francisco CA, US
Taiyin YANG - Monte Sereno CA, US

A61K 31/683
A61K 31/513
A61K 9/24
A61K 31/536

In accordance with this invention a novel pharmaceutical product containing efavirenz, emtricitabine and tenofovir DF are provided as a multicomponent unitary oral dosage form, component 1 comprising tenofovir DF (and, optionally, emtricitabine) and component 2 comprising efavirenz, wherein components 1 and 2 are in a stabilizing configuration. In preferred embodiments component 1 is made by dry granulation.